These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 3161742)

  • 1. Influence of renal failure on the kinetics of zimeldine and norzimelidine.
    Ferry N; Cuisinaud G; Cochat P; Pozet N; Zech PY; Sassard J
    Eur J Clin Pharmacol; 1985; 28(4):453-6. PubMed ID: 3161742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic study of zimelidine using a new GLC method.
    Caillé G; Kouassi E; de Montigny C
    Clin Pharmacokinet; 1983; 8(6):530-40. PubMed ID: 6228368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of zimelidine in humans--plasma levels and urinary excretion of zimelidine and norzimelidine after intravenous and oral administration of zimelidine.
    Love BL; Moore RG; Thomas J; Chaturvedi S
    Eur J Clin Pharmacol; 1981; 20(2):135-9. PubMed ID: 6455297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of food intake on the bioavailability of zimeldine and its active metabolite, norzimeldine.
    Wahlén A; Westerlund D; Wåhlin-Boll E; Melander A
    Drug Nutr Interact; 1983; 2(3):175-81. PubMed ID: 6236068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute kinetic and dynamic interactions of zimelidine with ethanol.
    Naranjo CA; Sellers EM; Kaplan HL; Hamilton C; Khouw V
    Clin Pharmacol Ther; 1984 Nov; 36(5):654-60. PubMed ID: 6237836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of ramipril in hypertensive patients with renal insufficiency.
    Schunkert H; Kindler J; Gassmann M; Lahn W; Irmisch R; Ritz E; Debusmann ER; Pujadas JO; Koch KM; Sieberth HG
    Eur J Clin Pharmacol; 1989; 37(3):249-56. PubMed ID: 2533075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of zimeldine in male alcoholics.
    Gottfries CG; Grind M; Lundström J; Alling C
    Acta Pharmacol Toxicol (Copenh); 1986 Aug; 59(2):94-102. PubMed ID: 2946168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic profile of flosequinan in patients with compromised renal function.
    Gallo BV; Hinson JL; Weidler DJ
    J Pharm Sci; 1993 Mar; 82(3):282-5. PubMed ID: 8450423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of metronidazole in patients with varying degrees of renal failure.
    Houghton GW; Dennis MJ; Gabriel R
    Br J Clin Pharmacol; 1985 Feb; 19(2):203-9. PubMed ID: 3986078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of renal impairment on the pharmacokinetics of levomilnacipran following a single oral dose of levomilnacipran extended-release capsule in humans.
    Chen L; Greenberg WM; Brand-Schieber E; Wangsa J; Periclou A; Ghahramani P
    Drug Des Devel Ther; 2015; 9():3293-300. PubMed ID: 26150701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of renal failure, rheumatoid arthritis and old age on the pharmacokinetics of diflunisal.
    Erikson LO; Wåhlin-Boll E; Odar-Cederlöf I; Lindholm L; Melander A
    Eur J Clin Pharmacol; 1989; 36(2):165-74. PubMed ID: 2721541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of renal insufficiency on the pharmacokinetics of cicletanine and its effects on the urinary excretion of electrolytes and prostanoids.
    Ferry N; Geoffroy J; Pozet N; Cuisinaud G; Benzoni D; Zech PY; Sassard J
    Br J Clin Pharmacol; 1988 Mar; 25(3):359-66. PubMed ID: 3358898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of oral and intravenous dolasetron mesylate in patients with renal impairment.
    Dimmitt DC; Shah AK; Arumugham T; Cramer MB; Halstenson C; Horton M; Weir SJ
    J Clin Pharmacol; 1998 Sep; 38(9):798-806. PubMed ID: 9753207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of famciclovir in subjects with varying degrees of renal impairment.
    Boike SC; Pue MA; Freed MI; Audet PR; Fairless A; Ilson BE; Zariffa N; Jorkasky DK
    Clin Pharmacol Ther; 1994 Apr; 55(4):418-26. PubMed ID: 8162668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of carteolol in relation to renal function.
    Hasenfuss G; Schäfer-Korting M; Knauf H; Mutschler E; Just H
    Eur J Clin Pharmacol; 1985; 29(4):461-5. PubMed ID: 4092726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nifedipine: influence of renal function on pharmacokinetic/hemodynamic relationship.
    Kleinbloesem CH; van Brummelen P; van Harten J; Danhof M; Breimer DD
    Clin Pharmacol Ther; 1985 May; 37(5):563-74. PubMed ID: 3987180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elimination of enoxacin in renal disease.
    Bury RW; Becker GJ; Kincaid-Smith PS; Moulds RF; Whitworth JA
    Clin Pharmacol Ther; 1987 Apr; 41(4):434-8. PubMed ID: 3470166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence of renal insufficiency and haemodialysis on the kinetics of ciprofibrate.
    Ferry N; Bernard N; Pozet N; Gardes E; Cuisinaud G; Labeeuw M; Zech PY; Sassard J
    Br J Clin Pharmacol; 1989 Dec; 28(6):675-81. PubMed ID: 2611089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of naproxen in subjects with normal and impaired renal function.
    Anttila M; Haataja M; Kasanen A
    Eur J Clin Pharmacol; 1980 Oct; 18(3):263-8. PubMed ID: 7439246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of cefonicid in uraemic patients.
    Fillastre JP; Fourtillan JB; Leroy A; Ramis N; Lefevre MA; Reumont G; Humbert G
    J Antimicrob Chemother; 1986 Aug; 18(2):203-11. PubMed ID: 3759731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.